<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304755</url>
  </required_header>
  <id_info>
    <org_study_id>2019/583</org_study_id>
    <nct_id>NCT04304755</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)</brief_title>
  <acronym>Z-AMD</acronym>
  <official_title>Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (The Z-AMD Study): A Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial&#xD;
      growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a one-year, randomized, controlled pilot study. A total of 40 treatment-naïve nAMD&#xD;
      patients will be allocated 1:1 to receive an intravenous infusion of either zoledronic acid&#xD;
      (ZA) 5 mg or placebo at baseline and after 26 weeks as adjuvant therapy to intravitreal&#xD;
      anti-VEGF injections in accordance with a treat and extend algorithm; bevacizumab is the&#xD;
      first-line treatment, and refractory eyes are converted to aflibercept.&#xD;
&#xD;
      The participants will be recruited among patients admitted to the Department of Ophthalmology&#xD;
      at Oslo University Hospital (OUH). The department is the largest provider of retinal care in&#xD;
      Norway and serves a local community of almost one million people, which makes it well-suited&#xD;
      for recruitment. Administration of ZA or placebo will take place at Pilestredet Park&#xD;
      Specialist Centre, an endocrinology clinic in Oslo with particular interest in treatment of&#xD;
      osteoporosis. The Clinical Trial Unit at OUH will monitor the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 13, 2021</start_date>
  <completion_date type="Anticipated">September 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in best-corrected visual acuity (BCVA) after 52 weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>To assess the change in best-corrected visual acuity measured by logMAR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of anti-VEGF intravitreal injections given after 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>To assess the number of anti-VEGF injections needed during 52 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a change in BCVA of 0.3 logMAR or more after 52 weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number of patients with a change in BCVA of 0.3 logMAR or more after 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with refractory nAMD after 52 weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of patients with refractory nAMD after 52 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ 5D score (ranging from 0-1; 0 designates &quot;perfect health&quot; and NEI-VFQ-25 score (ranging from 0 to 100 where 100 reflects best vision-specific health).</measure>
    <time_frame>52 weeks</time_frame>
    <description>EQ 5D score (ranging from 0-1; 0 designates &quot;perfect health&quot; and NEI-VFQ-25 score (ranging from 0 to 100 where 100 reflects best vision-specific health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Central retinal thickness (CRT) after 52 weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mean change from baseline in Central retinal thickness (CRT) after 52 weeks.To assess the proportion of patients with a considerable change in visual function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femoral fracture, endophthalmitis or orbital, scleral, or serious intraocular inflammation (grade 4 aqueous cells/FLARE).</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femoral fracture, endophthalmitis or orbital, scleral, or serious intraocular inflammation (grade 4 aqueous cells/FLARE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Investigational Medical Product : Zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zoledronic acid 5 mg IV at baseline and after 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: NaCl 0,9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 ml 0.9% NaCl IV at baseline and after 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic Acid 5 MG in 5 ML Injection</intervention_name>
    <description>Zoledronic acid</description>
    <arm_group_label>Investigational Medical Product : Zoledronic acid</arm_group_label>
    <other_name>ZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>NaCl 0.9%</description>
    <arm_group_label>Placebo: NaCl 0,9%</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Active, treatment-naïve neovascular AMD in the study eye, intraretinal or subretinal&#xD;
             fluid involving the fovea centre on optical coherence tomography (OCT), and evidence&#xD;
             of choroidal neovascularization on fluorescein angiography (FA) and/or OCT angiography&#xD;
             (OCT-A).&#xD;
&#xD;
          2. Age ≥50 years&#xD;
&#xD;
          3. Best-corrected visual acuity (BCVA) between 0.1 and 1.0 logMAR&#xD;
&#xD;
          4. Menopausal for at least one year&#xD;
&#xD;
          5. Only one eye per patient will be recruited for the study. If both eyes are eligible&#xD;
             for the study, the eye with the wors best-corrected Visual acuity (BCVA) will be&#xD;
             selected as the study eye.&#xD;
&#xD;
          6. Subjects must give written informed consent before any study related procedures are&#xD;
             performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lesions comprising more than 50% blood or fibrosis involving the fovea centre&#xD;
&#xD;
          2. Polypoidal choroidal vasculopathy (PCV) - indocyanine green (ICG) angiography is&#xD;
             performed at the discretion of the investigator on clinical suspicion of PCV&#xD;
&#xD;
          3. Presence of other ocular disease causing concurrent vision loss&#xD;
&#xD;
          4. Presence of ocular disease making intravitreal treatment contraindicated (e.g. current&#xD;
             ocular or periocular infection, active uveitis or uncontrolled glaucoma/intraocular&#xD;
             pressure ≥ 25 mmHg)&#xD;
&#xD;
          5. Systemic anti-vascular endothelial growth factor (anti-VEGF) or bisphosphonate&#xD;
             treatment within one year preceding the initial study treatment&#xD;
&#xD;
          6. Confirmed or suspected active malignancy&#xD;
&#xD;
          7. Other factors (i.e. lack of cooperation) that, in the opinion of the investigator, can&#xD;
             interfere with the study protocol&#xD;
&#xD;
          8. Known or suspected hypersensitivity to any of the trial products&#xD;
&#xD;
          9. Hypocalcemia (total Ca &lt; 2.15 mmol/L)&#xD;
&#xD;
         10. Renal impairment (estimated ClCR &lt; 35 ml/min).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten C Moe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten C Moe, MD, PhD</last_name>
    <phone>+47 23015166</phone>
    <email>mortmo@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Øystein K Jørstad, MD</last_name>
    <phone>+47 22118545</phone>
    <email>oeyjoe@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spesialistsenteret Pilestredet Park</name>
      <address>
        <city>Oslo</city>
        <zip>0176</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Erik F Eriksen, MD PhD</last_name>
      <phone>+47 22992700</phone>
      <email>efinkeriksen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Erik F Eriksen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo university hospital, Department of Ophthamology</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <contact>
      <last_name>Øystein K Jørstad, MD</last_name>
      <phone>+47 22118080</phone>
      <email>oeyjoe@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Øystein K Jørstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Morten Carstens Moe</investigator_full_name>
    <investigator_title>MD, Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>zoledronic acid</keyword>
  <keyword>anti-VEGF</keyword>
  <keyword>anti-vascular endothelial growth factor</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

